Glioblastoma treatment slowly moves toward change: novel druggable targets and translational horizons in 2022.
Lidia GattoEnrico FranceschiAlicia TosoniVincenzo Di NunnoStefania BartoliniAlba Ariela BrandesPublished in: Expert opinion on drug discovery (2023)
GBM molecular heterogeneity and brain anatomical characteristics critically restrain drug effectiveness. Nevertheless, stimulating insights for future research and drug development come from innovative treatment strategies for GBM, such as multi-specific 'off-the-shelf' CAR-T therapy, oncolytic viral therapy and autologous dendritic cell vaccination. Disappointing results from targeted therapies-clinical trials are mainly due to complex interferences between signaling pathways and biological processes leading to drug resistance: hence, it is imperative in the future to develop combinatorial approaches and multimodal therapies.
Keyphrases
- clinical trial
- dendritic cells
- current status
- signaling pathway
- randomized controlled trial
- stem cells
- single cell
- pain management
- resting state
- emergency department
- epithelial mesenchymal transition
- combination therapy
- brain injury
- immune response
- functional connectivity
- blood brain barrier
- single molecule
- electronic health record
- drug induced
- open label
- subarachnoid hemorrhage
- phase iii